Injectable contraception (medroxyprogesterone acetate) in rural Bangladesh
Parveen, L.; Chowdhury, A.Q.; Chowdhury, Z.
Lancet 2(8045): 946-948
1977
ISSN/ISBN: 0140-6736 PMID: 72288 DOI: 10.1016/s0140-6736(77)90887-xDocument Number: 279644
1601 women used the injectable contraceptive agent medroxyprogesterone acetate for up to 3 years. The programme was conducted by a rural health centre with detailed follow-up. While the continuation-rate, 56% after 1 year, compared favourably with that of other contraceptive methods in Bangladesh, at least half the women experienced troublesome menstrual side-effects and there were indications that milk yield was adversely affected in 147 out of the 1020 women who received the first injection while lactating.
Document emailed within 0-6 h
Related Documents
Kaunitz, A.M. 1994: Long-acting injectable contraception with depot medroxyprogesterone acetate American Journal of Obstetrics and Gynecology 170(5 Pt 2): 1543-1549Lech, M.M. 2003: Depot medroxyprogesterone acetate (DMPA) injectable contraception--safe, effective but neglected method of family planning in Poland Wiadomosci Lekarskie 56(7-8): 362-368
Lech, M.M. 2003: Depot medroxyprogesterone acetate (DMPA) injectable contraception--safe, effective but neglected method of family planning in Poland Wiadomosci Lekarskie 56(7-8): 362-368
Lech, M.M. 2003: Depot medroxyprogesterone acetate (DMPA) injectable contraception--safe, effective but neglected method of family planning in Poland Wiadomosci Lekarskie 56(7-8): 362-368
Stout, A.; Wood, S.; Barigye, G.; Kaboré, A.; Siddo, D.; Ndione, I. 2018: Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries Global Health Science and Practice 6(1): 55-72
Stout, A.; Wood, S.; Barigye, G.; Kaboré, A.; Siddo, D.; Ndione, I. 2018: Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries Global Health Science and Practice 6(1): 55-72
Stout, A.; Wood, S.; Barigye, G.; Kaboré, A.; Siddo, D.; Ndione, I. 2018: Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries Global Health Science and Practice 6(1): 55-72
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Govender, Y.; Avenant, C.; Verhoog, N.J.D.; Ray, R.M.; Grantham, N.J.; Africander, D.; Hapgood, J.P. 2014: The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor Plos one 9(5): E96497
Jawalekar, K.S.; Chitale, M.V. 1973: Medroxyprogesterone acetate as an injectable contraceptive--its utility in Indian women Journal of Obstetrics and Gynaecology of India 23(1): 55-57
Sathyamala, C.; Shah, P.; Jain, Y.; Bhargava, A. 1994: Use of injectable depot medroxyprogesterone acetate in lactating Indian women Lancet 344(8915): 134-135
Sathyamala, C.; Shah, P.; Jain, Y.; Bhargava, A. 1994: Use of injectable depot medroxyprogesterone acetate in lactating Indian women Lancet 344(8915): 134-135
Sathyamala, C.; Shah, P.; Jain, Y.; Bhargava, A. 1994: Use of injectable depot medroxyprogesterone acetate in lactating Indian women Lancet 344(8915): 134-135
Hu, E.; Ikeako, L.C.; Obiora-Okafor, N.C. 2012: The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 21(3): 266-271
Hu, E.; Ikeako, L.C.; Obiora-Okafor, N.C. 2012: The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 21(3): 266-271
Krashin, J.W.; Stuart, G.S.; Garrett, J.; Spector, H.; Bryant, A.G.; Charm, S.; Morse, J.E. 2017: Contraception Insurance Coverage and Receipt of Long-Acting Reversible Contraception or Depot Medroxyprogesterone Acetate on the Day of Abortion Obstetrics and gynecology 130(1): 109-117
Cursino, K.; Sider, M.; Pavin, E.J.ão.; dos Santos, P.d.N.é S.; Bahamondes, L.; Zantut-Wittmann, D.E.; Fernandes, A. 2016: Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use European Journal of Contraception and Reproductive Health Care: the Official Journal of the European Society of Contraception 21(1): 22-29
Nosaka, A.; Bairagi, R. 2008: Traditional Roles, Modern Behavior : Intergenerational Intervention and Contraception in Rural Bangladesh - Rôles traditionnels, conduites modernes : l'intervention intergenerationelle et la contraception dans le Bangladesh rural Human Organization 67(4): 407-416
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Tomasicchio, M.; Davids, M.; Pooran, A.; Theron, G.; Smith, L.; Semple, L.; Meldau, R.; Hapgood, J.Patricia.; Dheda, K. 2019: The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates Mycobacterium tuberculosis-Specific Host Immunity Through the Glucocorticoid Receptor Journal of Infectious Diseases 219(8): 1329-1337